1. Tranexamic acid and trauma: current status and knowledge gaps with recommended research priorities.
- Author
-
Pusateri AE, Weiskopf RB, Bebarta V, Butler F, Cestero RF, Chaudry IH, Deal V, Dorlac WC, Gerhardt RT, Given MB, Hansen DR, Hoots WK, Klein HG, Macdonald VW, Mattox KL, Michael RA, Mogford J, Montcalm-Smith EA, Niemeyer DM, Prusaczyk WK, Rappold JF, Rassmussen T, Rentas F, Ross J, Thompson C, and Tucker LD
- Subjects
- Antifibrinolytic Agents pharmacology, Humans, Postoperative Complications chemically induced, Randomized Controlled Trials as Topic, Research, Risk Factors, Seizures chemically induced, Thrombosis chemically induced, Tranexamic Acid pharmacology, Wounds and Injuries surgery, Antifibrinolytic Agents therapeutic use, Hemorrhage prevention & control, Tranexamic Acid therapeutic use, Wounds and Injuries drug therapy
- Abstract
A recent large civilian randomized controlled trial on the use of tranexamic acid (TXA) for trauma reported important survival benefits. Subsequently, successful use of TXA for combat casualties in Afghanistan was also reported. As a result of these promising studies, there has been growing interest in the use of TXA for trauma. Potential adverse effects of TXA have also been reported. A US Department of Defense committee conducted a review and assessment of knowledge gaps and research requirements regarding the use of TXA for the treatment of casualties that have experienced traumatic hemorrhage. We present identified knowledge gaps and associated research priorities. We believe that important knowledge gaps exist and that a targeted, prioritized research effort will contribute to the refinement of practice guidelines over time.
- Published
- 2013
- Full Text
- View/download PDF